Abstract
The Children's Cancer Group (CCG) found that children with moderate risk acute lymphoblastic leukemia (ALL) had an improved 5-year event-free survival (EFS) rate when treated with therapy that included a doubled delayed intensification (DDI) vs a single DI (SDI) phase. Because of increased toxicity with DDI, it is important to determine whether subgroups of children with ALL can be identified who have excellent outcomes with SDI therapy. TEL-AML1 fusion and hyperdiploid DNA content are present in the leukemic blasts of significant proportions of children with ALL and have been associated with an excellent prognosis. In this study, we retrospectively examined the impact of TEL-AML1 status and ploidy on treatment outcome in a cohort of 75 children with standard risk ALL treated at our institution between 1983 and 1993 with SDI therapy. TEL-AML1 fusion was present in 19/43 (44%) evaluable cases. Fifteen of 56 (27%) evaluable cases were classified as hyperdiploid based on a modal chromosome number of ≥ 51 and/or a DNA index of ≥ 1.16. The 7-year EFS was 81% for the 19 TEL-AML1-positive patients vs 54% for the 24 TEL-AML1-negative patients (P = 0.0264). In multivariate analyses, TEL-AML1-positive status was associated with a superior EFS (P = 0.02) even when the intial white blood count was included in the model. Overall survival (OS) at 7 years for TEL-AML1-positive patients was 100% vs 83% for TEL-AML1-negative patients (P = 0.0677). There were no differences in 7-year EFS or OS based on ploidy comparisons. These results underscore the need to examine closely the effects of treatment intensification on specific biologically defined subgroups of children with ALL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1708-1712 |
| Number of pages | 5 |
| Journal | Leukemia |
| Volume | 13 |
| Issue number | 11 |
| DOIs | |
| State | Published - 1999 |
| Externally published | Yes |
Funding
Fellowship Award from the National Childhood Cancer Foundation and was also supported by a University of Colorado Cancer Center seed grant. SPH is supported by a Professional Development Award from The Children’s Hospital Research Institute, Denver, CO and is a Leukemia Society of America Translational Research Awardee. This research was supported by a grant from the Children’s Cancer Research Fund (CCRF) and a Cancer Center Core Grant (CA 46934). The contents of this publication do not necessarily represent the policies or views of the CCRF.
| Funders | Funder number |
|---|---|
| Leukemia Society of America | |
| National Institute of Health-National Cancer Institute | P30CA046934 |
| National Childhood Cancer Foundation | |
| Arkansas Children’s Hospital Research Institute | |
| Cincinnati Children’s Research Foundation | |
| University of Colorado Cancer Center | |
| North of England Children’s Cancer Research Fund |
Keywords
- Childhood ALL
- Ploidy
- TEL-AML1
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS